Compare Citius Pharmaceuticals Inc (CTXR) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs DexCom, Inc. — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while DexCom, Inc. trades at $83.9 (market cap $31.86B). The key difference: DexCom, Inc. is far larger — about 2339.2× Citius Pharmaceuticals Inc's market cap, and DexCom, Inc. is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and DexCom, Inc. for 62 Days on average.
| CTXR | DXCM | |
|---|---|---|
Market Cap | $13.62M | $31.86B |
Volume | 132,438 | 3,607,070 |
Sector | Health | Health |
52-Week High | $1.82 | $92.34 |
52-Week Low | $0.48 | $54.84 |
Typical Hold Time | 16 Days | 62 Days |
Enterprise Value | $3.79M | $31.32B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
